NASDAQ · NPCE
Neuropace, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NPCE: Nov 3, 2026
Neuropace, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.11.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.15 | 2 |
| Dec 2026 | $-0.14 | $-0.13 | $-0.14 | 2 |
| Mar 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat- Zacks · Sep 10, 11:30 AM EDTWhy Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Sep 4, 9:58 AM EDTHere's Why You Should Retain NeuroPace Stock in Your Portfolio for NowNPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
- Zacks · Aug 17, 1:17 PM EDTNeuroPace Faces an IGE Delay: What the FDA Setback Means for GrowthNPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
- Zacks · Aug 17, 1:06 PM EDTIs NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
- Zacks · Aug 17, 12:59 PM EDTNPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
- Zacks · Aug 12, 11:22 AM EDTNPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View UpNeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
- MarketBeat · Aug 11, 8:04 PM EDTNeuroPace Q2 Earnings Call HighlightsNeuroPace (NASDAQ:NPCE) reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food
- Zacks · Aug 11, 5:25 PM EDTNeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue EstimatesNeuroPace (NPCE) delivered earnings and revenue surprises of +5.26% and +0.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 10:35 PM EDTCVRx (CVRX) Reports Q2 Loss, Beats Revenue EstimatesCVRx (CVRX) delivered earnings and revenue surprises of -1.92% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Jul 28, 6:04 PM EDTNeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More DataNeuroPace (NASDAQ:NPCE) said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant idiopathic generalized epilepsy, or IGE, was not approvable in its current form.
- Zacks · Jun 15, 9:55 AM EDTWall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to TradeThe mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Jun 11, 11:30 AM EDTNeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Neuropace, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.